Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

Seyed Jafari, S. Morteza; Feldmeyer, Laurence; Bossart, Simon; Simon, Dagmar; Schlapbach, Christoph; Borradori, Luca (2021). Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Frontiers in immunology, 11, p. 611549. Frontiers Research Foundation 10.3389/fimmu.2020.611549

[img]
Preview
Text
fimmu-11-611549.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (736kB) | Preview

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Jafari, Morteza; Feldmeyer, Laurence; Bossart, Simon; Simon, Dagmar; Schlapbach, Christoph and Borradori, Luca

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1664-3224

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Andrea Studer-Gauch

Date Deposited:

04 Jan 2022 15:34

Last Modified:

09 Jan 2022 01:51

Publisher DOI:

10.3389/fimmu.2020.611549

PubMed ID:

33584689

Uncontrolled Keywords:

bullous pemphigoid dupilumab omalizumab recalcitrant treatment

BORIS DOI:

10.48350/162120

URI:

https://boris.unibe.ch/id/eprint/162120

Actions (login required)

Edit item Edit item
Provide Feedback